<DOC>
	<DOCNO>NCT02084810</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate bioequivalence eptacog alfa A 6 mg NovoSeven® healthy male subject .</brief_summary>
	<brief_title>Investigating Bioequivalence Eptacog Alfa A 6 mg NovoSeven® Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Male , age 1855 year , inclusive , time signing informed consent Body Mass Index ( BMI ) 18.530 kg/m^2 , inclusive Good general health base assessment medical history , vital sign , physical examination , ECG ( electrocardiogram ) , laboratory data screening , judge investigator Known history thromboembolic event ( ) potential thromboembolic risk judge investigator</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>